Inhibition of human astrocyte and microglia neurotoxicity by calcium channel blockers

被引:55
|
作者
Hashioka, Sadayuki [1 ]
Klegeris, Andis [2 ]
McGeer, Patrick L. [1 ]
机构
[1] Univ British Columbia, Dept Psychiat, Kinsmen Lab Neurol Res, Vancouver, BC V6T 2A1, Canada
[2] Univ British Columbia, IK Barber Sch Arts & Sci, Dept Biol, Kelowna, BC V1V 1V7, Canada
关键词
Nimodipine; Verapamil; Astrocytes; Microglia; Interferon-gamma; STAT3; Neurodegeneration; NUCLEUS BASALIS MAGNOCELLULARIS; VERAPAMIL TREATMENT; ALZHEIMERS-DISEASE; RAT; NIMODIPINE; EXPRESSION; NEURONS; CELLS; NEUROPROTECTION; PHYSOSTIGMINE;
D O I
10.1016/j.neuropharm.2012.05.033
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
We examined the effects of L-type calcium channel blockers (CCBs) on toxicity exerted by activated human astrocytes and microglia towards SH-SY5Y human neuronal cells. The CCBs nimodipine (NDP) and verapamil (VPM) both significantly suppressed toxic secretions from human astrocytes and astrocytoma U-373 MG cells that were induced by interferon (IFN)-gamma. NDP also inhibited neurotoxic secretions of human microglia and monocytic THP-1 cells that were induced by the combination of lipopolysaccharide and IFN-gamma. In human astrocytes, both NDP and VPM reduced IFN-gamma-induced phosphorylation of signal transducer and activator of transcription (STAT) 3. They also inhibited the astrocytic production of IFN-gamma-inducible T cell alpha chemoattractant (I-TAC). These results suggest that CCBs attenuate IFN-gamma-induced neurotoxicity of human astrocytes through inhibition of the STAT3 signaling pathway. L-type CCBs, especially NDP, might be a useful treatment option for a broad spectrum of neurodegenerative diseases, including Alzheimer disease, where the pathology is believed to be exacerbated by neurotoxic glial activation. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:685 / 691
页数:7
相关论文
共 50 条
  • [21] Calcium channel blockers and headache
    Law, M. R.
    Morris, J. K.
    Wald, N. J.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 63 (02) : 157 - 158
  • [22] Calcium Channel Blockers and Hypertension
    Tocci, Giuliano
    Battistoni, Allegra
    Passerini, Jasmine
    Musumeci, Maria Beatrice
    Francia, Pietro
    Ferrucci, Andrea
    Volpe, Massimo
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2015, 20 (02) : 121 - 130
  • [23] Phenylalkylamines as calcium channel blockers
    Anamika Awasthi
    Arpita Yadav
    Journal of Chemical Sciences, 2007, 119 : 565 - 570
  • [24] CALCIUM-CHANNEL BLOCKERS
    RAY, D
    DYSON, D
    CLINICAL OBSTETRICS AND GYNECOLOGY, 1995, 38 (04): : 713 - 721
  • [25] CALCIUM-CHANNEL BLOCKERS
    WEINER, DA
    MEDICAL CLINICS OF NORTH AMERICA, 1988, 72 (01) : 83 - 115
  • [26] CALCIUM-CHANNEL BLOCKERS
    DIPALMA, JR
    AMERICAN FAMILY PHYSICIAN, 1983, 27 (02) : 283 - 285
  • [27] CALCIUM-CHANNEL BLOCKERS
    BELL, A
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 1990, 24 (04): : 444 - 445
  • [28] Calcium channel blockers and preconditioning
    Opie, LH
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2000, 32 (05) : 859 - 860
  • [29] Calcium channel blockers as tocolytics
    Economy, KE
    Abuhamad, AZ
    SEMINARS IN PERINATOLOGY, 2001, 25 (05) : 264 - 271
  • [30] CALCIUM-CHANNEL BLOCKERS
    JUTZY, RV
    WESTERN JOURNAL OF MEDICINE, 1985, 143 (01): : 94 - 95